Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine Biosciences names Sanjay Keswani chief medical officer, effective June 2, 2025

Neutral Impact 3 of 5 leadership Written later

Neurocrine Biosciences said Sanjay Keswani, M.D., will succeed Eiry W. Roberts, M.D., as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will remain with the company in a strategic advisory role. The change replaces a long-serving clinical leader with an executive who has more than 20 years of pharmaceutical industry experience.

Key points

  • Sanjay Keswani, M.D., agreed on April 2, 2025 to become Chief Medical Officer, effective June 2, 2025
  • Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years
  • Dr. Roberts previously announced her retirement in July 2023 and will stay on in a strategic advisory role
  • Dr. Keswani was previously President and CEO of ImmunoBrain and held R&D roles at Hoffmann-La Roche and Bristol-Myers Squibb

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECApr 4, 2025, 8:02 AM ET
Accession number0000914475-25-000081

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.